Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF and Darbepoetin for Decompensated Cirrhosis
NCT07131280Not yet recruiting
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Sep 2025
- Primary completion
- Jul 2031
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Randomised trial of filgrastim and darbepoetin alfa in decompensated cirrhosis (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Transplant-free survival at 3 years. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
filgrastimdarbepoetin alfa
03
Conditions
decompensated cirrhosis
Beyond the preview
Go deeper on NCT07131280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07131280.